<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111045</url>
  </required_header>
  <id_info>
    <org_study_id>09-OA-002</org_study_id>
    <nct_id>NCT01111045</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee</brief_title>
  <official_title>A Phase 2, Double Blind, Randomized, Placebo-Controlled, Proof of Concept, Dose Finding Study of Intraarticular Bone Morphogenetic Protein (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to evaluate the safety and efficacy of intraarticular BMP-7&#xD;
      for the treatment of osteoarthritis of the knee.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale.</measure>
    <time_frame>Baseline, and at 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.03 mg/ml BMP-7, single intraarticular knee injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/ml BMP-7, single intraarticular knee injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3 mg/ml BMP-7, single intraarticular knee injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 ml placebo, single intraarticular knee injection (control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bone morphogenetic protein 7</intervention_name>
    <description>Comparison of different doses of the drug via single intraarticular knee injection</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory with a diagnosis of OA of the knee with symptoms for at least 6 months and&#xD;
             pain on the majority of days in the last 30 days. Symptoms must include knee joint&#xD;
             pain.&#xD;
&#xD;
          -  A male or female adult age &gt;40 years&#xD;
&#xD;
          -  female subjects of childbearing potential must have a negative serum pregnancy test&#xD;
             during screening and a negative urine pregnancy test on the day of injection&#xD;
&#xD;
          -  Radiographic evidence of at least one tibiofemoral osteophyte and Osteoarthritis&#xD;
             Research Society International (OARSI) Atlas joint space narrowing grade of 1 or 2 in&#xD;
             the index knee&#xD;
&#xD;
          -  WOMAC pain score of &gt;8 at screening and baseline&#xD;
&#xD;
          -  Able to comply with the study and give informed consent&#xD;
&#xD;
          -  Able to read, write and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A requirement for treatment with opioids for pain relief.&#xD;
&#xD;
          -  Unwilling to abstain from NSAIDs and/or other analgesic medications for 48 hours and&#xD;
             acetaminophen for 24 hours prior to pain assessments during the study. Subjects taking&#xD;
             low dose aspirin for cardiovascular health may remain on their stable dose throughout&#xD;
             the study.&#xD;
&#xD;
          -  Using a handicap assistance device (i.e., cane, walker) &gt;50% of the time.&#xD;
&#xD;
          -  Undergoing new physical therapy or participating in a weight loss or exercise program&#xD;
             that has not been stable for at least 3 months prior to screening visit 1 and will not&#xD;
             remain stable during their participation in the study.&#xD;
&#xD;
          -  History of arthroscopic or open surgery to the index knee in the past 12 months or&#xD;
             planned surgery during study.&#xD;
&#xD;
          -  History of joint replacement surgery (index knee).&#xD;
&#xD;
          -  Received corticosteroid, short acting hyaluronic acid, or other intraarticular&#xD;
             injections of the index knee within 3 months of screening and/or not willing to&#xD;
             abstain from treatments for the duration of the study&#xD;
&#xD;
          -  Received long acting hyaluronic acid injection of the index knee within 6 months of&#xD;
             screening and/or not willing to abstain from treatments for the duration of the study.&#xD;
&#xD;
          -  History in the past 10 years of reactive arthritis, rheumatoid arthritis, psoriatic&#xD;
             arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel&#xD;
             disease, sarcoidosis, amyloidosis or fibromyalgia.&#xD;
&#xD;
          -  Clinical signs and symptoms of active knee infection or radiographic evidence of&#xD;
             crystal disease other than chondrocalcinosis (i.e., gout and CPPD).&#xD;
&#xD;
          -  A history of abnormal laboratory results ≥2.5 x ULN indicative of any significant&#xD;
             medical disease, which in the opinion of the investigator, would preclude the subjects&#xD;
             participation in the study&#xD;
&#xD;
          -  Any of the following abnormal laboratory results during screening:&#xD;
&#xD;
               1. ALT and AST ≥2.5x ULN&#xD;
&#xD;
               2. Hemoglobin &lt;11.5 g/dL (Female) or &lt;13.2 g/dL (Male)&#xD;
&#xD;
               3. WBC &lt;3500 cells/mm3&#xD;
&#xD;
               4. Lymphocyte count ≤1000 cells/mm3&#xD;
&#xD;
               5. Serum creatinine ≥1.5 x ULN&#xD;
&#xD;
               6. Platelet count below the central laboratory lower limit of normal.&#xD;
&#xD;
          -  History of malignancy in the past ten years (&lt;10 years), with the exception of&#xD;
             resected basal cell, squamous cell of the skin, resected cervical atypia or carcinoma&#xD;
             in situ.&#xD;
&#xD;
          -  Significant hip pain, ipsilateral to the index knee that may interfere with&#xD;
             assessments of index knee pain&#xD;
&#xD;
          -  Skin breakdown at the knee where the injection would take place&#xD;
&#xD;
          -  A known or clinically suspected infection with human immunodeficiency virus (HIV), or&#xD;
             hepatitis C or B viruses&#xD;
&#xD;
          -  Participated within 3 months or will participate concurrently in another&#xD;
             investigational drug or vaccine study&#xD;
&#xD;
          -  A history of drug or alcohol dependence or abuse in the past 3 years&#xD;
&#xD;
          -  Previous treatment with BMP-7 or any bone morphogenetic protein&#xD;
&#xD;
          -  A female with reproductive capability who is unwilling to use birth control for the&#xD;
             duration of the study and/or intends to conceive within 12 months of dosing.&#xD;
&#xD;
          -  Other serious, non-malignant, significant, acute or chronic medical or psychiatric&#xD;
             illness that, in the judgment of the investigator, could compromise subject safety,&#xD;
             limit the subject's ability to complete the study, and/or compromise the objectives of&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Research</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Arthritis Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center, Center for Aging</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robin Dore, MD, Inc</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulder Medical Center, PC</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of S. Florida</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Center for Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Medical Research, AMR, Inc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Bone and Joint Institute</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein &amp; Associates, MD, PA</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Center of Maryland</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research, PC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David R. Mandel, MD, Inc.</name>
      <address>
        <city>Mayfield Village</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Medical Research Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tacoma Center for Arthritis Research</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

